Abstract:Objective To determine the population pharmacokinetics of valproic acid(VPA) and identify the factors that explained PK variability in Chinese epileptic children.Methods 390 steady-state serum concentration samples were collected totally.The plasma samples for VPA concentration were analyzed using automated fluorescence polarization method(FPIA) with monoclonal antibodies.In total,321 patients aged 1.8(0.1-13.6) years and weighted 11.5(2.6-84) kg with 390 trough concentrations were extracted.Total body weight,VPA daily dose,gender and comedication with clonazepam,topiramate,carbamazepine,phenobarbital and oxcarbazepine were considered as covariates.A decrease of OFV(from basic model to covariate model) by more than 6.63 was considered to be statistically significant(P0.01,df=1).An increase of OFV from the full model of at least 10.83(P0.001,df = 1) was used as the chosen criterion for retaining the covariate in the model.Pharmacokinetic modeling was performed using NONMEM program(version 6,level 1.1) complied with G77 Fortran.A one-compartment pharmacokinetic model with first-order absorption and elimination(subroutine ADVAN2 and TRANS2) was used to describe the concentration-time data.The first-order conditional estimation method with η-e interaction(FOCE-I) was used throughout the model-building procedure.Various statistical models describing the random residual variability were considered.The reliability and stability of the population pharmacokinetic model developed was further assessed by a nonparametric bootstrap procedure.During this process,each patient was randomly sampled with replacement from the original data set to form new data set containing the same number of patients as the original data set.Results The final model for VPA apparent clearance(CL/F),including age(years),CLO comedication and liver enzyme inducer(carbamazepine or phenobarbital) covariates with a significant influence on this parameter,was as follows: CL/F=0.223·(Age/1.8)0.353·1.22CLO·1.36LEI,V=13.0·(Total body weight/11.5) where CLO was 1 when co-medicated with clonazepam preparation,otherwise CLO was 0;LEI was 1 when co-medicated with carbamazepine or phenobarbital preparation.The typical values for CL/F and apparent volume of distribution(V/F) were 0.223 L·h-1 and 13.0 L,respectively.Interindividual variability(coefficient of variation) for CL/F was 34.3% for final model and 51.5% for basic model;The residual unexplained variability was 25.6 %.In a single attempt of 200 bootstrap analysis,6(3.0%) runs terminated due to rounding errors and were excluded in the analysis.The parameter(except V/F) estimates from nonparametric bootstrap procedure were comparable and within 5% of the estimates from NONMEM.Conclusions A population pharmacokinetic model was proposed to estimate the individual CL/F for paediatric patients receiving VPA in terms of patient′s age,and concomitant clonazepam,carbamazepine or phenobarbital,in order to establish a prior dosage regimens.

Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers.

Population Pharmacokinetics of Lithium in Young Pediatric Patients with Intellectual Disability

Population Pharmacokinetics and Exposure-Response of Lithium Carbonate in Patients Based on Tubular Reabsorption Mechanisms

Population Pharmacokinetics Of Zonisamide After Oral Administration In Healthy Chinese Volunteers

Preliminary study on population pharmacokinetic model of metformin sustainedrelease tablets in healthy subjects

Population Pharmacokinetics of Ambroxol Hydrochloride in Chinese Healthy Male Subjects

Population pharmacokinetics of citalopram by NONMEM

Establish the Population Pharmacokinetics Model of Azithromycin in Chinese Healthy Volunteers

Population Pharmacokinetics of Valproate in Children with Epilepsy by NONMEM

[Population Pharmacokinetics of Lamotrigine in Chinese Children with Epilepsy].

Establishment of Population Phamacokinetic Model of Valproic Acid in Chinese Epileptic Children

Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling

Population Pharmacokinetics of Zolpidem Tartrate Tablets in Healthy Volunteers of Five Different Nationalities in China

Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients

Physiologically Based Pharmacokinetic Modeling of Lacosamide in Patients With Hepatic and Renal Impairment and Pediatric Populations to Support Pediatric Dosing Optimization

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.

Population Pharmacokinetics of Vancomycin and Prediction of Pharmacodynamics in the Chinese People

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy

Establishment of Population Pharmacokinetic Models with Valproic Acid in Different Age Groups of Chinese Epileptic Children

Assessment of Bioequivalence of Citalopram in Healthy Chinese Subjects by Population Pharmacokinetic Model

Population Pharmacokinetics Of Vancomycin In Chinese Pediatric Patients